# Helena A. Yu

Source: https://onco.cc/people/helena-yu/  
OnCo record `helena-yu` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Mapped how EGFR-mutant lung cancers resist osimertinib and led the HER3-directed ADC trials that followed.

## Summary

Helena A. Yu is a Medical Oncologist on the Thoracic Oncology Service at Memorial Sloan Kettering Cancer Center, specialising in EGFR-mutant lung cancer. She is known for mapping how EGFR-mutant lung cancers resist EGFR inhibitors such as osimertinib, including the T790M mutation and histological transformation, and for leading the HER3-directed antibody-drug conjugate trials that followed. Her selected papers analyse tumour specimens at the time of acquired resistance to EGFR inhibitors in 155 patients, and report HERTHENA-Lung01, a phase 2 trial of patritumab deruxtecan in EGFR-mutated lung cancer after prior therapy. She continues to study resistance mechanisms and ADCs in non-small-cell lung cancer.

## Fields

- Kind: Person
- Last checked: 2026-09-08
- Role: Medical Oncologist, Thoracic Oncology Service
- Specialisms: EGFR-mutant lung cancer; Resistance mechanisms; ADCs in lung cancer

## Sources

- MSK profile: https://www.mskcc.org/cancer-care/doctors/helena-yu
- PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=Yu%20HA%5BAuthor%5D

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- targets: [EGFR](https://onco.cc/targets/egfr/), [HER3](https://onco.cc/targets/her3/)
- drugs: [Osimertinib](https://onco.cc/drugs/osimertinib/), [Patritumab deruxtecan](https://onco.cc/drugs/patritumab-deruxtecan/)
- institutions: [Memorial Sloan Kettering Cancer Center](https://onco.cc/institutions/mskcc/)

---
JSON: https://onco.cc/api/v1/entities/helena-yu.json